Literature DB >> 23650165

Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

Kwok-Chiu Chang1, Wing-Wai Yew, Siu-Wai Cheung, Chi-Chiu Leung, Cheuk-Ming Tam, Chi-Hung Chau, Peter Kin-Ho Wen, Raphael Chiu-Yeung Chan.   

Abstract

We evaluated treatment with linezolid, dosed at 800 mg once daily for 1 to 4 months as guided by sputum culture status and tolerance and then at 1,200 mg thrice weekly until ≥ 1 year after culture conversion, in addition to individually optimized regimens among 10 consecutive patients with extensively drug-resistant tuberculosis or fluoroquinolone-resistant multidrug-resistant tuberculosis. All achieved stable cure, with anemia corrected and neuropathy stabilized, ameliorated, or avoided after switching to intermittent dosing. Serum linezolid profiles appeared better optimized.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23650165      PMCID： PMC3697330          DOI： 10.1128/AAC.00388-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.

Authors:  Won-Jung Koh; Yeh Rim Kang; Kyeonman Jeon; O Jung Kwon; Jiwon Lyu; Woo Sung Kim; Tae Sun Shim
Journal:  J Antimicrob Chemother       Date:  2012-03-08       Impact factor: 5.790

2.  A high performance liquid chromatography (HPLC) assay for linezolid in continuous ambulatory peritoneal dialysis fluid (CAPDF).

Authors:  C M Tobin; J Sunderland; A M Lovering; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2003-03-13       Impact factor: 5.790

Review 3.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

4.  Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.

Authors:  Robert S Wallis; Wesley M Jakubiec; Vikas Kumar; Annette M Silvia; Darcy Paige; Dessislava Dimitrova; Xiaoxi Li; Lynn Ladutko; Sheldon Campbell; Gerald Friedland; Mark Mitton-Fry; Paul F Miller
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

5.  Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.

Authors:  Robert S Wallis; Wesley Jakubiec; Vikas Kumar; Gabriella Bedarida; Annette Silvia; Darcy Paige; Tong Zhu; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Paul F Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

6.  Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.

Authors:  E E McKee; M Ferguson; A T Bentley; T A Marks
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

7.  Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Authors:  K N Williams; C K Stover; T Zhu; R Tasneen; S Tyagi; J H Grosset; E Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis.

Authors:  Dinesh Saralaya; Daniel G Peckham; Bill Hulme; Caroline M Tobin; Miles Denton; Steve Conway; Christine Etherington
Journal:  J Antimicrob Chemother       Date:  2004-01-16       Impact factor: 5.790

Review 9.  Peripheral neuropathy associated with prolonged use of linezolid.

Authors:  Adam M Bressler; Shanta M Zimmer; Jane L Gilmore; Jyoti Somani
Journal:  Lancet Infect Dis       Date:  2004-08       Impact factor: 25.071

10.  Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Won-Jung Koh; O Jung Kwon; Hyesun Gwak; Joo Won Chung; Sang-Nae Cho; Woo Sung Kim; Tae Sun Shim
Journal:  J Antimicrob Chemother       Date:  2009-05-25       Impact factor: 5.790
View more
  12 in total

1.  Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis.

Authors:  Daniel S Graciaa; Maia Kipiani; Matthew J Magee; Lali Mikiashvili; Ketevan Barbakadze; Nino Bablishvili; Sara C Auld; Wael A Alghamdi; Mohammad H Alshaer; Charles A Peloquin; Zaza Avaliani; Henry M Blumberg; Russell R Kempker
Journal:  Antimicrob Agents Chemother       Date:  2022-08-02       Impact factor: 5.938

Review 2.  WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Cheuk-Ming Tam; Chi-Chiu Leung
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

3.  Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Authors:  Zhiyi Lan; Nafees Ahmad; Parvaneh Baghaei; Linda Barkane; Andrea Benedetti; Sarah K Brode; James C M Brust; Jonathon R Campbell; Vicky Wai Lai Chang; Dennis Falzon; Lorenzo Guglielmetti; Petros Isaakidis; Russell R Kempker; Maia Kipiani; Liga Kuksa; Christoph Lange; Rafael Laniado-Laborín; Payam Nahid; Denise Rodrigues; Rupak Singla; Zarir F Udwadia; Dick Menzies
Journal:  Lancet Respir Med       Date:  2020-03-17       Impact factor: 30.700

4.  Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.

Authors:  Kristina M Bigelow; Rokeya Tasneen; Yong S Chang; Kelly E Dooley; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

5.  Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.

Authors:  Marco Schito; Giovanni Battista Migliori; Helen A Fletcher; Ruth McNerney; Rosella Centis; Lia D'Ambrosio; Matthew Bates; Gibson Kibiki; Nathan Kapata; Tumena Corrah; Jamshed Bomanji; Cris Vilaplana; Daniel Johnson; Peter Mwaba; Markus Maeurer; Alimuddin Zumla
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

Review 6.  Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging.

Authors:  Chi Chiu Leung; José M Porcel; Kazuhisa Takahashi; Marcos I Restrepo; Pyng Lee; Claire Wainwright
Journal:  Respirology       Date:  2014-02-21       Impact factor: 6.424

7.  Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.

Authors:  Sean Wasserman; Paolo Denti; James C M Brust; Mahmoud Abdelwahab; Siphokazi Hlungulu; Lubbe Wiesner; Jennifer Norman; Frederick A Sirgel; Robin M Warren; Aliasgar Esmail; Keertan Dheda; Neel R Gandhi; Graeme Meintjes; Gary Maartens
Journal:  Antimicrob Agents Chemother       Date:  2019-02-26       Impact factor: 5.191

8.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

9.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

Review 10.  Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?

Authors:  Wing Wai Yew; Won-Jung Koh
Journal:  Korean J Intern Med       Date:  2015-12-28       Impact factor: 2.884
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.